NEW YORK, April 4, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential security claims on behalf of shareholders of Sarepta Therapeutics, Inc. SRPT due to allegations that Sarepta has disclosed potentially materially misleading business information to the investing public.

SO WHAT: If you have purchased Sarepta securities, you may be entitled to compensation without payment of expenses or costs through a contingency fee arrangement. Law firm Rosen is preparing a class action lawsuit to recover investor losses.

WHAT TO DO NEXT: To participate in the prospective class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=1306 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email pkim@rosenlegal.com or cases@rosenlegal.com for information about the Class Action.

WHAT IS THIS ABOUT: On March 16, 2023, after the market close, the company issued a press release in which it “announced that the Office of Therapeutics of the U.S. Food and Drug Administration at its late-cycle meeting for the Biologics License Application (BLA) for SRP-9001 (delandistrogen moxeparvovec). (OTP) has determined that an Advisory Committee meeting for SRP-9001 will be held prior to the regulatory action date of May 29, 2023.”

As explained by the Investor’s Business Daily in an article titled “Sarepta Crashes at an Unexpected Roadblock for Its Gene Therapy,” the Food and Drug Administration’s decision came as a surprise. The article quotes a UBS analyst as saying: “In light of the announcement of the Advisory Committee’s decision, given that the Office of Therapeutics announces how limited its capacity is at every public appearance, we see a potential risk of an extension (of the approval date ). .”

As a result of this news, Sarepta’s share price fell $26.98, or 18%, to close at $122.69 per share on March 17, 2023, the next trading day.

WHY ROSES LAW: We encourage investors to seek qualified advisors with a track record in…